https://www.selleckchem.com/products/ms-275.html
4%; ≥75, 18.1%). Dose adjustments and discontinuation rates were slightly higher in older patients. Abemaciclib + ET improved PFS compared with placebo + ET independent of patient age, with no significant difference in abemaciclib treatment effect between the 3 age groups (MONARCH 2 interaction p-value, 0.695; MONARCH 3 interaction p-value, 0.634). Estimated hazard ratios ranged from 0.523-0.633 (MONARCH 2) and 0.480-0.635 (MONARCH 3). While higher rates of adverse events were reported in older patients, they were manageable with dose ad
Like
Comment
Share
